Daniel Isaacs is a senior associate in Goodwin’s Business Law Department. His practice focuses on advising emerging companies and investors throughout the corporate life cycle, including pre-incorporation planning and formation, venture capital and growth equity financings, mergers and acquisitions, public offerings, and general corporate representation and counseling. Mr. Isaacs represents clients in a variety of technology and life sciences industries, including digital health and healthcare, artificial intelligence and machine learning, cybersecurity, Fintech, blockchain and digital currency, new media, e-commerce, software, hardware, biotech, medical devices and diagnostics, and pharmaceuticals.

Mr. Isaacs is a member of Goodwin’s Hiring Committee.





A selection of Mr. Isaacs’s recent client representations includes:

Private Financings:

Company-Side Financings:

  • Aleta Biotherapeutics, an immuno-oncology company
  • Algorand, a blockchain and cryptocurrency company
  • Assured, a longevity risk management company 
  • BitSight Technologies, a risk management and cybersecurity company
  • Bolstr, Inc., an online lending platform
  • ClimaCell, a microweather platform
  • Fincura, an automated spreading, covenant monitoring, and borrower management platform
  • Fuze, a cloud-based unified communications provider
  • Humatics, a microlocation technology and spatial intelligence platform
  • Imagen Technologies, a medical technology company
  • Kyn Therapeutics, an immunometabolism therapies company
  • Libre Wireless Technologies, an embedded WiFi/wireless technology and software solutions provider
  • Mautic, an open-source marketing automation software company
  • Mavrck, an all-in-one influencer marking platform
  • Pellion Technologies, an innovator of next-generation battery technology
  • PureStake, a blockchain infrastructure for proof-of-stake networks
  • TCR2 Therapeutics, a biotech company developing a new generation of T cell therapies for patients suffering from cancer

Investor-Side Financings:

  • Amadeus Capital Partners, Atlas Venture, Bpifrance, Eni Next, General Catalyst Partners, Glasswing Ventures, Lightspeed Venture Partners, OMERS Ventures, OpenView Venture Partners, and Romulus Capital, in numerous investments in portfolio companies

Exit Transactions:

Sell-Side Representation:

  • Agilux Laboratories, a contract research organization and Ampersand Capital Partners’ portfolio company, in its sale to Charles River Laboratories International
  • Albany Molecular Research Inc., a contract research and manufacturing organization, in its sale to The Carlyle Group and GTCR
  • Confirm.io, an ID authentication platform, in its sale to Facebook
  • Fincura, in its sale to Numerated
  • Iconics, a global automation software provider, in its sale to Mitsubishi Electric Corporation
  • Litéra Corporation, a document lifecycle management company, in its sale to K1
  • PowerAdvocate, an energy intelligence company, in its sale to Verisk
  • Seniorlink, a tech-enabled health services company, in its sale to Thomas H. Lee Partners

Buy-Side Representation:

  • Ampersand Capital Partners and 1315 Capital in their acquisition of Genoptix, a provider of comprehensive testing solutions in hematology and solid tumor molecular profiling, from Novartis Pharmaceuticals Corporation
  • BitSight, in its acquisition of VisibleRisk, a cybersecurity risk assessment company
  • DaySmart, a provider of point-of-sale software, in its acquisition of PupKeep, a pet care software company
  • Fuze, in its acquisition of Parlai Technologies, a virtual assistant for customer-facing professionals
  • Imprivata, a healthcare IT security company and portfolio company of Thoma Bravo, in its acquisition of Caradigm, a healthcare analytics and management company and subsidiary of General Electric Company
  • Imprivata, in its acquisition of GroundControl, a mobile device software platform
  • Sansoro Health, a healthcare information technology company, in its acquisition of Datica, Inc., a cloud-based healthcare data platform

Public Offerings:

  • TCR2 Therapeutics, in connection with its initial public offering 

Strategic Transactions:

  • Negotiated numerous collaboration agreements with medical institutions on behalf of health tech and life science companies
  • Advised Quartet Medicine, a biotech company developing novel treatments for chronic pain and inflammation, in a cutting-edge build-to-buy transaction with Merck
  • Counseled investors in the corporate restructuring of a global clinical-stage biopharmaceutical company
  • Represented numerous cryptocurrency and digital asset companies and investors in connection with the launch and growth of blockchain-based platforms, node transactions, secondary node transactions, and digital asset sales and offerings, including Algorand, C3 ProtocolChainlink, JambbPureStakeBenchmark Capital, Borderless Relay, DavidsonKempner, Franklin Templeton, Glasswing Ventures, GoldenTree, and Lightspeed Venture Partners

Pro Bono Representation:

  • Accion, the largest nationwide nonprofit lending network in the United States
  • Building Markets, a non-profit organization that champions local entrepreneurs in developing countries
  • GLBTQ Legal Advocates & Defenders (GLAD), in connection with preparing a Supreme Court amicus brief in support of transgender student rights.
  • Neighborhood Business Initiative, a program to bring business and legal services to entrepreneurs and small-business owners who are members of underserved communities, or whose businesses service underserved neighborhoods
  • Project Citizenship, a nonprofit agency providing legal services to Massachusetts immigrants
  • Small Business Strong, a Boston Chamber of Commerce initiative to provide pro bono legal and business advice to small businesses
  • Led numerous workshops and presentations on corporate governance, entity formation, raising capital, and equity and debt financings with Lawyers for Civil Rights, BizGrow, Boston Public Library: Kirstein Business Library, Commonwealth Kitchen, Haley House, and Jewish Vocational Services
Professional Activities

Mr. Isaacs is a member of the Boston Bar Association.

Professional Experience

Prior to joining Goodwin, Mr. Isaacs was an associate in the New York office of Sullivan & Cromwell and served as a law clerk to the Honorable Pierre N. Leval of the U.S. Court of Appeals for the Second Circuit and the Honorable Robert H. Cleland of the U.S. District Court for the Eastern District of Michigan.

During law school, Mr. Isaacs served as a judicial intern to the Honorable Jack B. Jacobs on the Delaware Supreme Court.


Mr. Isaacs was recognized as a 2022 Up & Coming Lawyer by Massachusetts Lawyers Weekly.

Mr. Isaacs received the 2021 Robert B. Fraser Pro Bono Award, which is given annually by Goodwin to one associate and one partner that have made significant contributions to the firm’s pro bono efforts.

While attending law school, Mr. Isaacs was a senior editor for the Yale Law Journal and an editor-in-chief for the Yale Journal of Health Policy, Law and Ethics. He also served as Student Director of the San Francisco Affirmative Litigation Project (SFALP) and the President of the American Constitution Society (ACS).

Additionally, while at Yale Law School, Mr. Isaacs was awarded the William K.S. Wang Prize for superior performance in corporate law.

In The News









J.D., 2012
Yale Law School
B.A., 2009
University of Pennsylvania


2013 to 2014 U.S. Court of Appeals for the Second Circuit, Honorable Pierre N. Leval
2014 to 2015 U.S. District Court for the Eastern District of Michigan, Honorable Robert H. Cleland



New York


U.S. District Court for the Southern District of New York
U.S. District Court for the Eastern District of New York
U.S. District Court for the Eastern District of Michigan
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique